Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $17.0 million.

  • Cumberland Pharmaceuticals' Cost of Revenue rose 0.83% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 2.55%. This contributed to the annual value of $17.0 million for FY2024, which is 7.74% down from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Cost of Revenue stood at $17.0 million, which was down 7.74% from $18.5 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Cost of Revenue ranged from a high of $18.5 million in FY2023 and a low of $14.8 million during FY2020.
  • For the 3-year period, Cumberland Pharmaceuticals' Cost of Revenue averaged around $17.4 million, with its median value being $17.0 million (2024).
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Cost of Revenue rose by 10.96% in 2022 and then declined by 7.74% in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' Cost of Revenue (Yearly) stood at $14.8 million in 2020, then increased by 1.69% to $15.0 million in 2021, then increased by 10.96% to $16.7 million in 2022, then rose by 10.75% to $18.5 million in 2023, then declined by 7.74% to $17.0 million in 2024.